Solu-Cortef 500 mg inj. opl. (pdr.) i.v./i.m. flac. बेल्जियम - डच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

solu-cortef 500 mg inj. opl. (pdr.) i.v./i.m. flac.

pfizer sa-nv - hydrocortisonnatriumsuccinaat 668,35 mg - eq. hydrocortison 500 mg - poeder voor oplossing voor injectie - 500 mg - hydrocortisonnatriumsuccinaat 668.35 mg - hydrocortisone

Solu-Cortef S.A.B. Act-O-Vial 100 mg inj. opl. (pdr. + oplosm.) i.v./i.m. flac. बेल्जियम - डच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

solu-cortef s.a.b. act-o-vial 100 mg inj. opl. (pdr. + oplosm.) i.v./i.m. flac.

pfizer sa-nv - hydrocortisonnatriumsuccinaat 66,835 mg/ml - eq. hydrocortison 50 mg/ml - poeder en oplosmiddel voor oplossing voor injectie - 100 mg - hydrocortisonnatriumsuccinaat 66.835 mg/ml - hydrocortisone

Solu-Cortef S.A.B. Act-O-Vial 500 mg inj. opl. (pdr. + oplosm.) i.v./i.m. flac. बेल्जियम - डच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

solu-cortef s.a.b. act-o-vial 500 mg inj. opl. (pdr. + oplosm.) i.v./i.m. flac.

pfizer sa-nv - hydrocortisonnatriumsuccinaat 167,088 mg/ml - eq. hydrocortison 125 mg/ml - poeder en oplosmiddel voor oplossing voor injectie - 500 mg - hydrocortisonnatriumsuccinaat 167.088 mg/ml - hydrocortisone

Solu-Cortef S.A.B. Act-O-Vial 250 mg inj. opl. (pdr. + oplosm.) i.v./i.m. flac. बेल्जियम - डच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

solu-cortef s.a.b. act-o-vial 250 mg inj. opl. (pdr. + oplosm.) i.v./i.m. flac.

pfizer sa-nv - hydrocortisonnatriumsuccinaat 167,09 mg/ml - eq. hydrocortison 125 mg/ml - poeder en oplosmiddel voor oplossing voor injectie - 250 mg - hydrocortisonnatriumsuccinaat 167.09 mg/ml - hydrocortisone

Onbevzi यूरोपीय संघ - डच - EMA (European Medicines Agency)

onbevzi

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische middelen - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. zie rubriek 5 voor meer informatie over de status van humane epidermale groeifactorreceptor 2 (her2). onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. raadpleeg sectie 5 voor meer informatie over her2-status. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Tranylcypromine Double-e Pharma 10 mg, filmomhulde tabletten नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

tranylcypromine double-e pharma 10 mg, filmomhulde tabletten

double-e pharma limited 17 corrig road 18 dublin (ierland) - tranylcyprominesulfaat 13,7 mg/stuk samenstelling overeenkomend met ; tranylcypromine 10 mg/stuk - filmomhulde tablet - allurarood ac aluminium lak (e 129) ; cellulose, microkristallijn (e 460(i)) ; karmijn (e120) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171), allurarood ac aluminium lak (e 129) ; cellulose, microkristallijn (e 460) ; karmijn (e120) ; macrogol 3350 ; magnesiumstearaat (e 470b) ; maÏszetmeel, gepregelatineerd ; polyvinylalcohol, gedeeltelijk gehydrolyseerd (e1203) ; siliciumdioxide (e 551) ; talk (e 553 b) ; titaandioxide (e 171)

Medrol 32 mg tabl. बेल्जियम - डच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

medrol 32 mg tabl.

pfizer sa-nv - methylprednisolon 32 mg - tablet - methylprednisolone

Citraplax 20 mg/ml, druppels voor oraal gebruik, oplossing नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

citraplax 20 mg/ml, druppels voor oraal gebruik, oplossing

chanelle medical - escitalopramoxalaat samenstelling overeenkomend met ; escitalopram - druppels voor oraal gebruik, oplossing - citroenzuur 0-water (e 330) ; ethanol 96 % 94 mg/ml ; natriumhydroxide (e 524) ; propylgallaat (e 310) ; water, gezuiverd, - escitalopram

Escitalopram 10 mg ratiopharm, filmomhulde tabletten नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

escitalopram 10 mg ratiopharm, filmomhulde tabletten

ratiopharm gmbh - escitalopramoxalaat samenstelling overeenkomend met; escitalopram; - filmomhulde tablet - escitalopram

Escitalopram 15 mg ratiopharm, filmomhulde tabletten नीदरलैंड - डच - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

escitalopram 15 mg ratiopharm, filmomhulde tabletten

ratiopharm gmbh - escitalopramoxalaat samenstelling overeenkomend met ; escitalopram - filmomhulde tablet - cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; hypromellose (e 464) ; macrogol 400 ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; stearinezuur (e 570) ; titaandioxide (e 171), - escitalopram